Seqens CDMO North America (formerly known as PCI Synthesis) has appointed Jean-Noel David as Managing Director for North America. He replaces Ed Price, co-founder and president of the business, who will continue to serve as a consultant.
David’s mission is to grow Seqens’ CDMO business in North America, which includes plans to add manufacturing capacity, equipment and staff. Based on his experience as Vice President for Business Transformation at Patheon Biologics, where he led the integration of acquisitions, he will also continue to integrate U.S. operations with capacity and resources available throughout Seqens’ 24 manufacturing sites and R&D centers around the world.
“As co-founder and CEO, Ed did an outstanding job establishing the API development business, as evidenced by dozens of industry awards the business unit has been won year after year. Building on those strengths and adding our international capabilities, we believe there is room to grow our manufacturing capabilities with the same dedication to quality, efficiency and service for which Seqens CDMO North America has become the gold standard,” David said. “Due to COVID-19, more customers are looking to develop alternatives to their current supply chain and are asking for our help. The combined capabilities of Seqens North America and Europe, where Seqens is very well-known, ideally positions us to help them in new ways.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
David’s global experience, having lived and worked on five continents and speaking four languages, will help current and prospective sponsors tap additional Seqens’ resources, equipment and expertise. He earned an MBA from the Goizueta Business School at Emory University, received a Master’s of Science from ENSTA Paris and a bachelor’s degree from the Pierre and Marie Curie University. He settled in the United States over 20 years ago. He will relocate to the Boston area.